Fundraising Fox

Amir Nashat

Investor

Entrepreneur Partner at Polaris Partners

Cambridge, Massachusetts

Writes $300K – $2M checks · typically $500K

FoundedAgbiomeaTYR PHARMACamp4 Therapeutics CorpDewpoint TherapeuticsFate TherapeuticsMetacrine

About

Amir Nashat is an entrepreneur partner in Polaris Partners' Boston office who joined the firm in 2002 and serves as a managing partner of Polaris Funds VI–IX. He focuses on portfolio company executive roles and investing in healthcare companies, and is currently CEO of Souffle Therapeutics. He earned an ScD in Chemical Engineering with a minor in Biology at MIT as a Hertz Fellow under Robert Langer, and holds MS and BS degrees in Materials Science and Mechanical Engineering from UC Berkeley.

Invests in

BiotechHealthtech

Experience

  1. Soufflé TherapeuticsChief Executive Officercurrent2021 — present
  2. CAMP4 TherapeuticsBoard Membercurrent2016 — presentCambridge, Massachusetts, United States
  3. Dewpoint TherapeuticsBoard Membercurrent2018 — presentBoston, Massachusetts, United States
  4. Dewpoint TherapeuticsChief Executive Officer2018 — 2020
  5. Institute for Protein InnovationBoard Membercurrent2017 — present
  6. Polaris Venture PartnersEntrepreneur Partnercurrent2021 — present
  7. Polaris Venture PartnersManaging General Partner2002 — 2021
  8. Polaris Venture PartnersManaging Partner2002 — 2021Boston, Massachusetts, United States
  9. AgBiomeBoard Member2012 — 2024
  10. Morphic TherapeuticBoard Member2017 — 2024
  11. Scholar RockBoard Member2012 — 2024Cambridge, Massachusetts
  12. Metacrine, Inc.Board Member2014 — 2023La Jolla, California
  13. Paratus SciencesChief Executive Officer2020 — 2022New York City Metropolitan Area
  14. Syros PharmaceuticalsBoard Member2014 — 2022Cambridge, Massachusetts
  15. FreenomeBoard Member2019 — 2021
  16. Fate Therapeutics IncBoard Member2008 — 2020
  17. Jnana TherapeuticsCEO2017 — 2018
  18. Promedior, Inc.Board Member2008 — 2018Greater Boston Area
  19. Receptos, Inc.Board Member2012 — 2014
  20. AVILA THERAPEUTICS, INC.Board Member2007 — 2012

Education

  1. Massachusetts Institute of TechnologyPhD, Chemical Engineering1996 — 2002
  2. University of California, BerkeleyMSc, Materials Science Engineering1994 — 1996
  3. University of California, BerkeleyBSc, Mechanical Engineering1990 — 1994

Same school

Shared employers

Deals · 15

Morphic Holding, Inc.Board seat

via Polaris Partners · filed Mar 2023 · $100M raise

Camp4 Therapeutics CorpBoard seat

via Polaris Partners · filed Jun 2022

AgbiomeBoard seat

via Polaris Partners · filed Feb 2022 · $117.2M raise

Dewpoint TherapeuticsBoard seat

via Polaris Partners · filed Feb 2022 · $150M raise

Syros Pharmaceuticals, Inc.Board seat

via Polaris Partners · filed Dec 2020 · $121.6M raise

Primmune TherapeuticsBoard seat

via Polaris Partners · filed Nov 2020 · $24M raise

Freenome HoldingsBoard seat

via Polaris Partners · filed Aug 2020 · $270M raise

Cartesian Therapeutics (NASDAQ: RNAC)Board seat

via Polaris Partners · filed Jan 2020 · $70M raise

Scholar Rock Holding Corp, Inc.Board seat

via Polaris Partners · filed Jan 2018 · $47M raise

Sofregen MedicalBoard seat

via Polaris Partners · filed Sep 2017 · $9.7M raise

MetacrineBoard seat

via Polaris Partners · filed Nov 2016 · $37.8M raise

Fate TherapeuticsBoard seat

via Polaris Partners · filed Aug 2016 · $10.3M raise

1366 TechnologiesBoard seat

via Polaris Partners · filed May 2016 · $30M raise

Scholar RockBoard seat

via Polaris Partners · filed Jan 2016 · $40M raise

aTYR PHARMABoard seat

via Polaris Partners · filed Apr 2015 · $76.3M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at Polaris Partners

Network5

Investors connected to Amir in public investor directories — a warm-intro map.